Immunome Price Target Maintained With a $35.00/Share by Wedbush

What happened

Wedbush maintained its price target of $35.00 per share for Immunome, according to ratings actions reported by Benzinga. The article provides no further details about the rating or the reasoning behind the maintained target.

Confirmed

Global impact / market context

A maintained price target signals that Wedbush's view on Immunome's value has not changed recently. Investors often watch analyst targets as one reference point for expected share performance, though a target alone does not confirm future returns.

Analyst inference

The article gives only the target and no rating change, financial results, or company news. Without broader context, readers cannot tell whether this target is above or below the current share price or what assumptions support it.

Analyst inference

What to watch

1. Wedbush maintained a $35.00 per share price target on Immunome, per the supplied article. Confirmed
2. Watch for any future Wedbush update that changes the rating or target, since a revision would show a shift in the analyst's view. Proposed
3. Compare the $35.00 target with Immunome's actual share price to judge whether the analyst expects gains or sees limited room ahead. Analyst inference

Evidence

• Original source link unavailable